Less than a tenth of individuals who could benefit from weight-loss injections like Wegovy are able to get them, states the World Health Organization as it releases its initial guidance on the therapies.
Given over a billion individuals worldwide now classified as obese, it is calling for broader and more equitable access to this class of drugs.
According to projections, more than two billion will be living with obesity by 2030 unless action is taken.
"The new guidance affirms that obesity is a chronic disease that can be addressed with comprehensive and lifelong treatment," said its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are major barriers to broad availability to the injections that can assist patients in reducing considerable body mass, notes the organization.
Skinny Jab Scarcity
Despite the present best projected case, the supply of such drugs might only reach around 100 million people – fewer than 10% of eligible patients, per the health organization.
The advice calls on countries and companies to expand availability, by measures including voluntary licensing.
A patent on the active ingredient – the core ingredient of a leading brand – is set to lapse in several nations in 2026.
How Weight-Loss Jabs Work
GLP-1 drugs mimick a natural hormone to delay gastric emptying, curb appetite and enhance feelings of fullness so people reduce food intake.
People commonly begin shedding pounds within a few weeks of beginning the weekly injections.
Research indicates users may regain a significant portion a year later of discontinuing the medication, as their usual hunger return.
Being overweight or obese elevates your chance for experiencing diseases, including diabetes, cardiovascular issues, brain attack, and certain malignancies.
Excess weight impacts people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.
